Data as of Jan 30
| +0.08 / +0.18%|
The 19 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.06, with a high estimate of 54.54 and a low estimate of 33.52. The median estimate represents a -3.48% decrease from the last price of 45.65.
The current consensus among 19 polled investment analysts is to Buy stock in Novozymes A/S. This rating has held steady since January, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.